Ivacaftor/lumacaftor

Ivacaftor/lumacaftor Reactions 1704, p215 - 2 Jun 2018 Osteopenia, height loss and non-traumatic compression fractures : case report A 19-year-old man developed osteopenia, height loss and non-traumatic compression fractures during treatment with ivacaftor/lumacaftor for cystic fibrosis. The man who had fat-soluble vitamin deficiency and osteopenia, was hospitalised for the treatment of a cystic fibrosis (CF) pulmonary exacerbation and a weight loss. He had been taking ivacaftor/lumacaftor [route and dosage not stated] for approximately 18 months for CF. On admission, a review of his growth chart showed a height loss of 8.5cm over the previous 5 months. One month before the admission, a dual energy X-ray absorption (DEXA) scan was significant for osteopenia. He was started on treatment for cystic fibrosis (CF) pulmonary exacerbation and was continued on ivacaftor/ lumacaftor. On further questioning, he reported a mild intermittent back pain over the previous six months. His musculoskeletal physical examination remained normal, except from the loss in height. A lumbar spine X-ray showed a superior end-plate fracture of L1 and a chest computed tomography scan showed the incidental finding of significant height loss of multiple mid-thoracic vertebrae. At follow-up, a total spine MRI revealed evidence of chronic compression fractures at the level of T5 through L1 [duration of treatment to reactions onset not stated]. The man was treated colecalciferol and pamidronic acid [outcomes not stated]. Author comment: "Lumacaftor/ivacaftor therapy was initiated in our patient approximately 18 months prior to his presentation." "[I]t is important to consider the possibility of this medication having an impact on bone health." Schendel A, et al. Unexpected Height Loss in an Adolescent With Cystic Fibrosis Global pediatric health 5: 1-4, 22 May 2018. Available from: URL: https:// dx.doi.org/10.1177/2333794X18773662 - USA 803323012 0114-9954/18/1704-0001/$14.95 Adis © 2018 Springer International Publishing AG. All rights reserved Reactions 2 Jun 2018 No. 1704 http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Reactions Weekly Springer Journals

Ivacaftor/lumacaftor

Reactions Weekly , Volume 1704 (1) – Jun 2, 2018
Free
1 page

Loading next page...
1 Page
 
/lp/springer-journals/ivacaftor-lumacaftor-N7wQmaRlOp
Publisher
Springer Journals
Copyright
Copyright © 2018 by Springer International Publishing AG, part of Springer Nature
Subject
Medicine & Public Health; Drug Safety and Pharmacovigilance; Pharmacology/Toxicology
ISSN
0114-9954
eISSN
1179-2051
D.O.I.
10.1007/s40278-018-46858-3
Publisher site
See Article on Publisher Site

Abstract

Reactions 1704, p215 - 2 Jun 2018 Osteopenia, height loss and non-traumatic compression fractures : case report A 19-year-old man developed osteopenia, height loss and non-traumatic compression fractures during treatment with ivacaftor/lumacaftor for cystic fibrosis. The man who had fat-soluble vitamin deficiency and osteopenia, was hospitalised for the treatment of a cystic fibrosis (CF) pulmonary exacerbation and a weight loss. He had been taking ivacaftor/lumacaftor [route and dosage not stated] for approximately 18 months for CF. On admission, a review of his growth chart showed a height loss of 8.5cm over the previous 5 months. One month before the admission, a dual energy X-ray absorption (DEXA) scan was significant for osteopenia. He was started on treatment for cystic fibrosis (CF) pulmonary exacerbation and was continued on ivacaftor/ lumacaftor. On further questioning, he reported a mild intermittent back pain over the previous six months. His musculoskeletal physical examination remained normal, except from the loss in height. A lumbar spine X-ray showed a superior end-plate fracture of L1 and a chest computed tomography scan showed the incidental finding of significant height loss of multiple mid-thoracic vertebrae. At follow-up, a total spine MRI revealed evidence of chronic compression fractures at the level of T5 through L1 [duration of treatment to reactions onset not stated]. The man was treated colecalciferol and pamidronic acid [outcomes not stated]. Author comment: "Lumacaftor/ivacaftor therapy was initiated in our patient approximately 18 months prior to his presentation." "[I]t is important to consider the possibility of this medication having an impact on bone health." Schendel A, et al. Unexpected Height Loss in an Adolescent With Cystic Fibrosis Global pediatric health 5: 1-4, 22 May 2018. Available from: URL: https:// dx.doi.org/10.1177/2333794X18773662 - USA 803323012 0114-9954/18/1704-0001/$14.95 Adis © 2018 Springer International Publishing AG. All rights reserved Reactions 2 Jun 2018 No. 1704

Journal

Reactions WeeklySpringer Journals

Published: Jun 2, 2018

There are no references for this article.

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off